(IN BRIEF) Novartis has finalized its US manufacturing and research expansion plan with the announcement of a seventh new facility in Morrisville, North Carolina, dedicated to producing active pharmaceutical ingredients for solid-dose medicines and RNA therapies. The move is part … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged API production, biotechnology, Carlsbad California, Denton Texas, drug development, Healthcare Innovation, Indianapolis Indiana, Millburn New Jersey, Morrisville, North Carolina, Novartis, Novartis Finalizes $23 Billion US Expansion Program Enhancing Domestic Manufacturing and Research Infrastructure, Novartis Strengthens US Production Network with New Facility Supporting Advanced Therapies and Supply Chain Resilience, pharmaceutical manufacturing, radioligand therapy, RNA therapeutics, San Diego research center, supply chain resilience, US expansion, Vas Narasimhan, Winter Park Florida
(IN BRIEF) SGS has introduced GMP-compliant NMR testing capabilities in China using a JEOL 400 MHz system, strengthening its pharmaceutical analytical services with advanced structural and quantitative analysis. The new offering supports the entire drug development and manufacturing lifecycle by … Read the full press release
Posted in Business, Financial, Government, Industrial, Investment, Management, Marketing, Pharma & Biotech, Security & Safety, Switzerland, Technology
Tagged Analytical Chemistry, API analysis, China laboratory services, drug development, GMP compliance, impurity profiling, JEOL 400 MHz, NMR testing, pharmaceutical manufacturing, Pharmaceutical Testing, polymorphism, quality control, quantitative NMR, regulatory compliance, SGS, SGS Expands Pharmaceutical Testing Capabilities in China with GMP Compliant NMR Technology, SGS Introduces Advanced NMR Testing Service to Strengthen Drug Quality Control in China
(IN BRIEF) The European Investment Bank has provided €100 million in financing to Orion Pharma to support the development of new treatments for cancer, pain, and other conditions with limited therapeutic options. The funding will be used for research and … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Finland, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical industry, clinical trials, Critical Medicines Alliance, drug development, EIB, EU resilience, European Investment Bank, European Investment Bank and Orion Pharma Expand Collaboration to Boost Healthcare Innovation and Supply Security, Healthcare Innovation, Karl Nehammer, oncology, Orion Pharma, pain treatment, pharmaceutical research, R&D investment, René Lindell, €100 Million EIB Investment Supports Orion Pharma Development of Critical Medicines and Therapies
(IN BRIEF) Sandoz is celebrating 20 years since the approval of Omnitrope, the world’s first biosimilar medicine, which helped establish a new pharmaceutical category and expand patient access to biologic treatments. Since its launch, Omnitrope has generated significant healthcare savings … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Alfred Kern, biologics, biosimilar market, biosimilars, drug development, Edouard Sandoz, European Medicines Agency, global healthcare, growth hormone therapy, healthcare savings, Omnitrope, Omnitrope Anniversary Underscores Sandoz Leadership and Future Potential of Biosimilars in Transforming Patient Access, patient access, pharmaceutical industry, Richard Saynor, Sandoz, somatropin
(IN BRIEF) Sanofi has announced positive phase 2 clinical results for lunsekimig, a novel bispecific therapy targeting key inflammatory pathways in respiratory diseases. The treatment successfully met primary and key secondary endpoints in studies involving moderate-to-severe asthma and chronic rhinosinusitis … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged asthma treatment, atopic dermatitis, biologic therapy, chronic rhinosinusitis with nasal polyps, clinical trials, CRSwNP, drug development, Houman Ashrafian, IL13, lunsekimig, Nanobody VHH, Phase 2 study, respiratory diseases, Sanofi, Sanofi Advances Respiratory Pipeline with Promising Clinical Data for Dual Targeting Lunsekimig Therapy, Sanofi Reports Positive Phase 2 Results for Lunsekimig in Asthma and Respiratory Diseases Development, TSLP
(IN BRIEF) GSK has announced that China’s National Medical Products Administration has accepted for review a New Drug Application for bepirovirsen, an investigational antisense oligonucleotide designed to treat adults with chronic hepatitis B. The submission is supported by Phase III … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, Science, United Kingdom
Tagged antisense oligonucleotide, ASO therapy, B-Well 1 trial, B-Well 2 trial, Bepirovirsen, breakthrough therapy designation, CHB, China healthcare, chronic hepatitis B, clinical trials, drug development, functional cure, GSK Moves Closer to Transforming Chronic Hepatitis B Care with Bepirovirsen NDA Review in China, GSK plc, GSK Strengthens Infectious Disease Portfolio with Regulatory Submission for Novel Hepatitis B Therapy in China, HBsAg, hepatitis B surface antigen, infectious disease, liver cancer, National Medical Products Administration, NMPA, viral infection
(IN BRIEF) Sandoz has announced a new partnership with Samsung Bioepis to develop and commercialize up to five biosimilar medicines, beginning with a vedolizumab biosimilar targeting inflammatory bowel diseases. The agreement grants Sandoz global commercialization rights in most markets, while … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged affordable medicines, Alexion, biologics, biosimilar pipeline, biosimilars, commercialization agreement, Crohn disease, drug development, eculizumab, Entyvio, Epysqli, global healthcare, inflammatory bowel disease, pharmaceutical partnership, pouchitis, Pyzchiva, Richard Saynor, Samsung Bioepis, Sandoz, Sandoz and Samsung Bioepis Deepen Alliance to Capture Growing Biosimilar Market Opportunity Worldwide, Sandoz Secures Global Commercialization Rights in New Biosimilar Agreement with Samsung Bioepis, Soliris, Takeda, Ulcerative colitis, ustekinumab, vedolizumab
(IN BRIEF) Researchers at the Technical University of Munich have developed a new drug candidate that significantly enhances the effectiveness of the antibiotic metronidazole against Helicobacter pylori, a bacterium linked to stomach cancer. By introducing targeted chemical modifications, the team … Read the full press release
Posted in Chemicals, Education, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Science, Technology
Tagged antibiotic resistance, biotechnology, drug development, Helicobacter pylori, Marianne Pandler, Markus Gerhard, metronidazole, Michael Groll, Michaela Fiedler, microbiome, Nature Microbiology, Oxidative stress, Stephan A. Sieber, stomach cancer, Technical University of Munich, TUM, TUM Researchers Achieve Breakthrough in Antibiotic Enhancement with New Compound Showing Strong Activity Against Resistant Bacteria
(IN BRIEF) GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary diseases. The acquisition includes HS235, an investigational activin signalling inhibitor … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 35Pharma, activin signalling inhibitor, biotechnology acquisition, CANADA, cardiopulmonary diseases, clinical trials, drug development, GSK, GSK Targets Next Generation Pulmonary Hypertension Treatments with Acquisition of 35Pharma, GSK to Acquire 35Pharma for 950 Million Dollars to Strengthen Pulmonary Hypertension Drug Pipeline, HS235, Ilia Tikhomirov, PH-HFpEF, pharmaceutical industry, pulmonary arterial hypertension PAH, pulmonary hypertension, Respiratory Immunology and Inflammation portfolio, Tony Wood
(IN BRIEF) Basilea Pharmaceutica has partnered with INCATE, the European incubator for antibacterial therapies, to support the advancement of early-stage anti-infective innovations. As an industry partner, Basilea brings deep expertise in antibacterial and antifungal drug development, while expanding INCATE’s scope … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Non Profit, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged anti-infectives, antibacterial therapies, antifungal therapies, antimicrobial resistance, Basel life sciences, Basilea Joins INCATE to Advance Early-Stage Antibacterial and Antifungal Innovation in Europe, Basilea Pharmaceutica, biopharmaceutical innovation, clinical development, drug development, INCATE, industry partnership, infectious diseases, invasive fungal infections, Laurenz Kellenberger, preclinical research, Primo Schär, University of Basel
(IN BRIEF) Boehringer Ingelheim has licensed a pre-clinical small molecule program from Kyowa Kirin to develop a potential first-in-class therapy for autoimmune diseases, a major global health challenge affecting around 10% of the population. The deal grants Boehringer exclusive worldwide … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged autoimmune diseases, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim Secures Exclusive Global Rights to Develop New Autoimmune Treatment from Kyowa Kirin, Boehringer Ingelheim Strengthens Autoimmune Disease Pipeline with Licensing Agreement from Kyowa Kirin, Carine Boustany, chronic inflammation, drug development, global health, immunology, inflammatory diseases, Kyowa Kirin, licensing agreement, pharmaceutical innovation, pre-clinical program, respiratory diseases, small molecule therapy, Takeyoshi Yamashita
(IN BRIEF) GSK has signed an exclusive global licensing agreement with Empirico Inc. for EMP-012, a first-in-class siRNA candidate currently in Phase I trials for chronic obstructive pulmonary disease (COPD). EMP-012 targets a distinct inflammatory pathway, offering potential therapeutic benefit … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biologics, Chronic obstructive pulmonary disease, COPD, drug development, EMP-012, Empirico, gene expression, genetic medicine, GSK, GSK Acquires Global Rights to Empirico’s siRNA Candidate EMP-012 for Chronic Obstructive Pulmonary Disease, GSK and Empirico Partner on First-in-Class siRNA Therapy EMP-012 to Address Unmet Needs in COPD, Healthcare Innovation, inflammation, inflammation pathway, Kaivan Khavandi, licensing agreement, oligonucleotide therapeutics, Omri Gottesman, Phase I clinical trial, precision medicine, respiratory diseases, respiratory pipeline, siRNA, type 2 inflammation
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) The University of Twente, Medisch Spectrum Twente, and the Centre for Human Drug Research (CHDR) will open a new clinical research unit at MST on 10 October 2025. This expansion represents CHDR’s first facility outside Leiden and underscores … Read the full press release
Posted in Education, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Centre for Human Drug Research, Centre for Human Drug Research opens new clinical unit at Medisch Spectrum Twente in partnership with University of Twente, CHDR, clinical research, clinical trials, drug development, Enschede, Healthcare Innovation, Leiden BioScience Park, Leiden University, Leiden University Medical Centre, medical technology, Medisch Spectrum Twente, MST, New clinical research unit at MST marks next step in partnership between University of Twente and Centre for Human Drug Research, TechMed Centre, therapeutic innovation, Twente, University of Twente, University of Twente and partners launch new Centre for Human Drug Research clinical research unit to advance therapeutic innovation in Twente, University of Twente joins CHDR and MST to position Twente as a hub for medical technology and therapeutic development, University of Twente joins forces with CHDR and Medisch Spectrum Twente to open new clinical research unit in Twente, UT
(IN BRIEF) Merck and Siemens have signed a new Memorandum of Understanding that expands their collaboration in life sciences and focuses on accelerating digital transformation across drug discovery, development, and manufacturing. The partnership integrates Merck’s life science SaaS tools and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Germany, Healthcare, Management, Pharma & Biotech, Science, Technology
Tagged AI, automation, biomanufacturing, Cedrik Neike, data management, digital innovation, digitalization, Dotmatics, drug development, drug discovery, Expanded Merck-Siemens partnership targets connected digital workflows to accelerate scientific discovery and production, Jean-Charles Wirth, life sciences, Luma, Merck, SaaS, scientific progress, Siemens, Siemens and Merck strengthen alliance with new MoU to advance automation AI and digitalization in life sciences, Siemens Xcelerator, smart manufacturing
(IN BRIEF) ZEISS Research Microscopy Solutions and Concept Life Sciences have formed a partnership to accelerate innovation in spatial biology by focusing on workflow automation, AI-powered analysis, and assay development. The collaboration introduces advanced imaging solutions such as the ZEISS … Read the full press release
Posted in Business, Electronics & Machinery, Germany, Healthcare, Investment, News, Science, Technology, United Kingdom
Tagged AI-powered imaging, biomarker discovery, cancer research, CLS, Concept Life Sciences, CRO partnerships, Dr Florian Leiss, Dr Hayley Gooding, drug development, IHC, image analysis, Mindpeak, multiplex immunofluorescence, SlideStream, spatial biology, translational research, workflow automation, ZEISS, ZEISS and Concept Life Sciences partner to advance automation and AI-driven analysis in spatial biology workflows, ZEISS Axioscan 7, ZEISS joins forces with Concept Life Sciences to deliver scalable imaging solutions for spatial biology and translational medicine, ZEISS Research Microscopy Solutions
(IN BRIEF) Researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine and Hannover Medical School have developed an innovative cardiac organoid model that simulates a miniature, functional heart to test the cardiotoxicity of new medications. Comprising heart muscle cells, … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged biomedical research, cardiac organoid, cardiotoxicity, drug development, Drug Safety, Fraunhofer, Fraunhofer ITEM, Hannover Medical School, hiPSCs, hypertrophic cardiomyopathy, immune system, induced pluripotent stem cells, macrophages, RNA Therapies
(IN BRIEF) ZEISS has launched the Axioscan 7 spatial biology, a high-performance slide scanner designed for clinical research applications in spatial biology. The system supports high-throughput, automated imaging for multiplex immunofluorescence (mIF) assays, providing researchers with faster, more efficient, and … Read the full press release
Posted in Business, Electronics & Machinery, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged AI-powered image analysis, automated scanning, Axioscan 7, biomarker discovery, clinical research, Dr. Michael Albiez, drug development, fluorescence imaging, high-performance slide scanner, high-throughput, LIMS, microscopy, MIF, multiplex immunofluorescence, research automation, spatial biology, translational research, Ultivue, ZEISS
(IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged autoimmune diseases, B cell depletion, biologics innovation, biopharma collaboration, bispecific compound, Boehringer Ingelheim, Carine Boustany, chronic disease treatment, Cue Biopharma, CUE-501, Daniel Passeri, drug development, Immuno-STAT, Immuno-STAT platform, immunology pipeline, inflammatory diseases, licensing agreement, memory T cells, milestone payments, partnership, precision medicine, royalty payments, strategic partnership, T cell engagers, targeted biologics, up-front payment
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?